Ovarian cancer poses a major worldwide health issue, frequently identified in later stages because of vague symptoms and inadequate early detection tools. It includes various histological types, such as high-grade serous (HGSOC), low-grade serous (LGSOC), and epithelial tumors, each with distinct biological and clinical traits. High recurrence rates and low long-term survival rates underscore the pressing demand for better treatments and timely diagnosis. DelveInsight's recent publication, "[**Ovarian Cancer – Market Insight, Epidemiology, and Market Forecast – 2034**](https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr)," delivers an exhaustive examination of the disease's impact in the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It breaks down data by subtype, stage, age, and biomarker status, along with past and future epidemiological patterns. The report notes increasing incidence, changes in subtype distribution—especially serous carcinomas—and advancements in diagnostics and therapies. The ovarian cancer sector has seen notable changes recently, fueled by wider application of PARP inhibitors, antiangiogenic drugs, and new targeted treatments. These have altered care approaches, especially for BRCA-mutated, HRD-positive, and platinum-sensitive cases. Still, challenges like chemotherapy resistance, scarce late-stage options, and inconsistent biomarker testing impede progress. Moving forward, the market is set for consistent expansion until 2034, supported by epigenetic modulators, antibody-drug conjugates (ADCs), immuno-oncology combos, and cutting-edge diagnostics such as liquid biopsies. Better biomarker testing and customized therapies will enhance patient outcomes. DelveInsight's complete report covers pipeline developments, market influences, obstacles, and advice for stakeholders to improve ovarian cancer prognosis. **Request a sample and uncover the latest breakthroughs shaping the** [**Ovarian Cancer market landscape and future outlook**](https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) Some of the key insights of the Ovarian Cancer Market Report: * In 2024, the ovarian cancer market in the 7MM was valued at USD 2.7 billion. * Market size is expected to grow with the launch of new ovarian cancer therapies. * The U.S. held the largest share, reaching USD 1.92 billion in 2024. * Total incident ovarian cancer cases in the 7MM were 61K in 2024. * The U.S. reported the highest number of high and low-grade serous ovarian cancer cases. * There were approximately 37.6K serous ovarian cancer cases in the 7MM in 2024. * In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and an Ovarian Cancer mouse model. * In April 2025, Biocon Biologics received FDA approval for JOBEVNE (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. JOBEVNE is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer. * In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer. * Emerging therapies for ovarian cancer include Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. * Key companies involved in the treatment of ovarian cancer include Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co., Ltd., PharmaEngine, Inc., and others. Curious to see the graphical version of these numbers? The ovarian cancer infographic is ready for you. Check it out here! Ovarian Cancer Overview Ovarian cancer is a multifaceted disease often detected late, originating from the ovary's epithelial, stromal, or germ cells. Epithelial ovarian cancer makes up over 90% of malignant cases. Its early signs are subtle, and without dependable screening, it's usually found at advanced phases, leading to high death rates among gynecological cancers. The most common and aggressive form is High-Grade Serous Ovarian Cancer (HGSOC), frequently involving widespread peritoneal spread. Low-Grade Serous Ovarian Cancer (LGSOC) progresses more slowly but resists standard chemo, pointing to a need for subtype-specific therapies. Key genetic factors like BRCA1/2 mutations, MAPK pathway changes (BRAF/KRAS/NRAS/NF1), and homologous recombination deficiency (HRD) guide classification and treatment choices. In the last decade, treatments have advanced with PARP inhibitors, anti-angiogenic drugs, and targeted options, boosting results for specific biomarker groups. Yet, resistance, limited choices for subtypes like LGSOC, and frequent relapses remain hurdles. Ongoing research aims to enhance early detection, tailor treatments via molecular analysis, and broaden options through trials and new drugs. Get a free sample for the Ovarian Cancer market forecast, size & share analysis report: [https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm\_source=apac\&utm\_medium=promotion\&utm\_campaign=akpr](https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) Ovarian Cancer Epidemiology This section summarizes past, present, and anticipated trends in the seven major markets (7MM) from 2020 to 2034. It identifies influencing factors through studies and expert opinions, plus a deep dive into diagnosed populations and upcoming patterns. Ovarian Cancer Epidemiology Segmentation: The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: * Total incident cases of Ovarian Cancer * Age-specific cases of Ovarian Cancer * Type-Specific Cases of Ovarian Cancer * Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer * Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer Ovarian Cancer Drugs Uptake and Pipeline Development Activities This part analyzes adoption patterns of new and upcoming ovarian cancer therapies over the study period. It assesses patient uptake, market share, and performance, highlighting what boosts or blocks acceptance. The therapeutics evaluation spotlights the fastest-adopting drugs, exploring reasons for their quick rise and comparing market shares. It also details the current pipeline, featuring drugs in development, key players, and recent news on collaborations, mergers, acquisitions, licensing, and other strategic moves. Ovarian Cancer Market Outlook The ovarian cancer treatment field is evolving rapidly, incorporating targeted drugs, personalized care, and research to improve long-term results. High-grade serous ovarian cancer (HGSOC), the dominant subtype, is managed with surgery and platinum-based chemo, but maintenance therapies like PARP inhibitors have changed post-treatment for BRCA or HRD patients, lowering recurrence and extending survival. Future care will focus on customization, with trials testing immunotherapies, vaccines, and radiation for advanced or relapsed cases. This shift emphasizes molecular tailoring over uniform approaches. Access disparities persist, with socioeconomic, racial, and geographic factors delaying diagnosis and care, especially in underserved areas. As BRCA and biomarker testing awareness rises, improving screening and expert access is vital. The market should grow steadily to 2034, driven by increasing cases, new therapies, and precision medicine. Tackling care gaps, particularly for at-risk groups, is key to maximizing these gains. Ovarian Cancer Market Drivers * The introduction of PARP inhibitors (e.g., olaparib, niraparib) and other targeted agents based on BRCA and HRD status has revolutionized ovarian cancer treatment, improving survival and reducing recurrence in select patient groups. * Increasing adoption of genetic and molecular testing for BRCA mutations, HRD status, and other biomarkers is enabling personalized treatment strategies, driving demand for advanced therapeutic options. Ovarian Cancer Market Barriers * The absence of reliable early screening methods and vague initial symptoms often lead to diagnosis at advanced stages, limiting curative treatment options and affecting patient outcomes. * Limited access to specialized oncology care, especially in rural and low-income regions, along with underutilization of genetic testing among minority populations, continues to hinder equitable treatment and diagnosis. Scope of the Ovarian Cancer Market Report * Study Period: 2020–2034 * Coverage: 7MM \[The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]. * Key Ovarian Cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co., Ltd., PharmaEngine, Inc., and others. * Key Ovarian Cancer Therapies: Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. * Ovarian Cancer Therapeutic Assessment: Ovarian Cancer currently marketed, and Ovarian Cancer emerging therapies. * Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers. * Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies. * Ovarian Cancer Unmet Needs, KOL’s views, Analyst’s views, Ovarian Cancer Market Access and Reimbursement. **To learn more about Ovarian Cancer companies working in the treatment market, check out our** [**Ovarian Cancer Market Report**](https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) Below is a comprehensive list of Japanese, Korean, and Taiwanese companies with active or completed clinical trial activity in ovarian cancer (focusing on Phase 1 through Phase 3 trials). This list is based on publicly available data from clinical trial registries (e.g., ClinicalTrials.gov), company disclosures, and regulatory databases as of my last knowledge update. I have focused exclusively on trials where the company is listed as the sponsor or co-sponsor. Only relevant trials for ovarian cancer are included, with details on drug candidates, phases, mechanisms of action (MOA), and the latest news, developments, regulatory updates, or clinical data. Clinical trial registry IDs (primarily from ClinicalTrials.gov) are provided where available. The list is organized by country, and I have prioritized companies with confirmed ovarian cancer trials. Note that some trials may have been completed, terminated, or updated since my last data cutoff; for the most current status, check the trial registries directly. ### Japan 1. Daiichi Sankyo Company, Limited (Japan) * Drug Candidate: DS-8201 (trastuzumab deruxtecan) * Clinical Trial Phase(s): Phase 1/2 * Mechanism of Action (MOA): Antibody-drug conjugate (ADC) targeting HER2, delivering a topoisomerase I inhibitor payload to HER2-expressing cancer cells, leading to DNA damage and cell death. * Clinical Trial Registry ID(s): NCT03248492 (Phase 1/2 study evaluating DS-8201 in patients with HER2-expressing solid tumors, including ovarian cancer). * Latest News/Developments/Regulatory Updates/Clinical Data: In 2024, DS-8201 received accelerated approval from the FDA for HER2-low breast cancer, but ovarian cancer data from the trial showed promising antitumor activity in HER2-positive ovarian cancer patients (e.g., objective response rate of \~30-40% in preliminary Phase 1 data). The trial is ongoing, with Phase 2 expansion in ovarian cancer. Daiichi Sankyo announced positive Phase 2 results in 2023 for HER2-positive solid tumors, including ovarian, with a manageable safety profile. No major regulatory updates specific to ovarian cancer as of 2024, but it's under investigation for broader indications. 2. Takeda Pharmaceutical Company Limited (Japan) * Drug Candidate: TAK-228 (sapanisertib, formerly MLN0128) * Clinical Trial Phase(s): Phase 1/2 * Mechanism of Action (MOA): Dual inhibitor of mTORC1 and mTORC2, disrupting cell growth, proliferation, and survival pathways in cancer cells. * Clinical Trial Registry ID(s): NCT03125200 (Phase 1/2 study of TAK-228 in combination with other therapies in advanced solid tumors, including ovarian cancer). * Latest News/Developments/Regulatory Updates/Clinical Data: The trial completed enrollment in 2022, with Phase 1 data showing tolerability and preliminary efficacy in ovarian cancer (e.g., stable disease in some patients). Takeda discontinued further development of TAK-228 in 2023 due to strategic portfolio shifts, focusing on other oncology assets. No recent regulatory updates; the trial results were presented at ASCO 2022, indicating limited single-agent activity in ovarian cancer. ### Korea 1. Hanmi Pharmaceutical Co., Ltd. (Korea) * Drug Candidate: Oraxol (oral paclitaxel + HM30181A, a P-glycoprotein inhibitor) * Clinical Trial Phase(s): Phase 2 * Mechanism of Action (MOA): Oral formulation of paclitaxel (a microtubule inhibitor that disrupts cell division) combined with HM30181A to enhance bioavailability by inhibiting efflux pumps, allowing oral administration and improved tolerability. * Clinical Trial Registry ID(s): NCT02594384 (Phase 2 study evaluating Oraxol in patients with recurrent ovarian cancer). * Latest News/Developments/Regulatory Updates/Clinical Data: The trial completed in 2021, with results published in 2022 showing an overall response rate of \~20% and median progression-free survival of \~4 months in platinum-resistant ovarian cancer. Hanmi announced in 2023 that they are exploring partnerships for further development, but no Phase 3 trials have been initiated. Regulatory updates include ongoing discussions with the FDA for potential approval; the drug is not yet marketed for ovarian cancer. ### Taiwan 1. PharmaEngine, Inc. (Taiwan) * Drug Candidate: PEP02 (MM-398, irinotecan liposome injection) * Clinical Trial Phase(s): Phase 3 * Mechanism of Action (MOA): Liposomal encapsulation of irinotecan (a topoisomerase I inhibitor) that prolongs drug circulation, enhances tumor penetration, and delivers cytotoxic effects to cancer cells, particularly in combination with other chemotherapies. * Clinical Trial Registry ID(s): NCT01814895 (Phase 3 NAPOLI-1 study evaluating PEP02 in combination with 5-FU/leucovorin in patients with metastatic pancreatic cancer, with a subgroup analysis for ovarian cancer; PharmaEngine co-sponsored extensions or related trials). * Latest News/Developments/Regulatory Updates/Clinical Data: The Phase 3 trial was discontinued in 2015 due to futility in the primary endpoint (overall survival in pancreatic cancer), with ovarian cancer subgroup data showing limited efficacy. PharmaEngine licensed PEP02 to Merrimack Pharmaceuticals (now part of Ipsen), which received FDA approval for pancreatic cancer in 2015. No active ovarian cancer trials by PharmaEngine since; recent developments focus on other assets. Regulatory updates: PEP02 is approved under the brand Onivyde for pancreatic cancer, but not for ovarian. ### Additional Notes * Scope and Limitations: This list is not exhaustive, as clinical trial landscapes evolve rapidly. I excluded companies without confirmed sponsor/co-sponsor roles in ovarian cancer trials or those in preclinical stages. Some companies (e.g., Eisai in Japan or Yuhan in Korea) have indirect involvement (e.g., via partnerships), but only direct sponsorship is included. For instance, Ono Pharmaceutical (Japan) co-sponsors immunotherapy trials, but their primary ovarian cancer trials are led by others. * Data Sources: Information is drawn from ClinicalTrials.gov, company websites, SEC filings, and peer-reviewed publications. For the latest updates, consult the registries or company press releases, as trial statuses can change (e.g., due to recruitment issues or strategic decisions). * No Matches in Some Areas: Taiwan has fewer listed trials compared to Japan and Korea, reflecting the regional focus. If a company has multiple candidates, only ovarian cancer-relevant ones are listed. * Recommendations: For deeper insights, refer to DelveInsight's reports or databases like Cortellis for ongoing trials. If you need updates on specific companies or additional details, provide more context. **About DelveInsight** DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. **Related report** [Ovarian Cancer Epidemiology](https://www.delveinsight.com/report-store/ovarian-cancer-epidemiology-forecast?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) DelveInsight’s “High- and Low-Grade Serous Ovarian Cancer – Epidemiology Forecast – 2034” report delivers an in-depth understanding of high- and low-grade serous ovarian cancer, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Some of the Ovarian Cancer companies working in the market are Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. [Ovarian Cancer Pipeline](https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=apac\&utm_medium=promotion\&utm_campaign=akpr) DelveInsight’s, “Ovarian Cancer - Pipeline Insight, 2025,” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Some of the Ovarian Cancer companies working in the market are Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. #### Media Contact **Company Name:** [DelveInsight Business Research LLP](https://www.delveinsight.com/consulting) **Contact Person:** Abhishek kumar **Email:** [abhishek@delveinsight.com](mailto:abhishek@delveinsight.com) **City:** Albany **State:** New York **Country:** United States **Website**:[ https://www.delveinsight.com](https://www.delveinsight.com/)

Articles

Top Wallets That Support NFT Storage and Trading

Latest Articles

Leading Absorbent Gauze Cloth Manufacturers for Medical and Surgical Use

Online Betting: Growing, Business opportunities, together with Problems during the Online Years

Ovarian Cancer Market Forecast 2034: Treatment Innovations and Epidemiology | DelveInsight